The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

Phase 4 Unknown 12 enrolled Ottawa Hospital Research Institute

NaSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to measure change in raltegravir serum pharmacokinetics in steady state, when co-administered with calcium carbonate formulated as antacid.

Timeline

Start: 2020-12-09
Primary completion: 2024-06-15
Completion: 2025-01-01

Publications

Teixeira Nunes Porto LL, Doyle MA, Zhang G, Tremblay N, Yazji B, Kanji S, Cameron DW. Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada. BMJ Open. 2025 Jul 5;15(7):e094384. doi: 10.1136/bmjopen-2024-094384.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Calcium carbonate	Other / unclassified	500 mg	Oral
Subject	Calcium carbonate	Other / unclassified	1000 mg	Oral
Subject	Raltegravir	Other / unclassified	1200 mg	Oral

Indications

No indication recorded.